Hematology

Axicabtagene ciloleucel delivered superior overall survival compared with standard of care in patients with early relapsed or refractory large B-cell lymphoma.

Patients with advanced-stage Hodgkin lymphoma who received nivolumab plus AVD experienced a 1-year estimated progression-free survival rate of 94% meeting the primary end point of the phase 3 SWOG S1826 trial.

Treatment with imetelstat elicited statistically significant and clinically meaningful improvements in transfusion independence among patients with lower-risk myelodysplastic syndrome.

Updated National Comprehensive Cancer Network guidelines recommend ropeginterferon alfa-2b for patients with polycythemia vera.

Jessica MacIntyre, DNP, MBA, APRN, NP-C, AOCNP, describes how nurses used an app imbedded in the electronic medical record to refer patients to the Leukemia & Lymphoma Society.

Pediatric patients with leukemia in low- and middle-income countries saw improvements in survival outcomes following implementation of the WHO Framework for Action model.

Over half of patients with lower-risk myelodysplastic syndrome treated with luspatercept achieved transfusion independence.

Fit patients with chronic lymphocytic leukemia achieved high undetectable minimal residual disease rates with frontline venetoclax combinations.

The FDA has approved avapritinib for the treatment of patients with indolent systemic mastocytosis.

Donna Catamero, ANP-BC, OCN, CCRC, highlights best nursing practices with teclistamab.

The FDA has granted epcoritamab accelerated approval for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma. The prescribing label comes with boxed warnings for cytokine release syndrome and neurologic problems.

An analysis of the cilta-cel safety profile yielded promising results, according to nurse investigators.

Victoria R. Crowder, BSN, RN, and co-investigators, highlight existing gaps in the understanding of malnutrition risks facing patients with acute myeloid leukemia and myelodysplastic syndromes.

Monitoring patients for cytokine release syndrome is a key aspect of caring for patients receiving teclistamab.

Specialists highlight the best practices and latest treatment regimens for patients presenting with myelofibrosis, polycythemia vera, and essential thrombocythemia.

The FDA has pushed back the PDUFA date for quizartinib for select patients with acute myeloid leukemia.

Data that was leaked from a 2023 EHA Hybrid Congress Abstracts demonstrated that ciltacabtagene autoleucel reduced the risk of disease progression in patients with relapsed/refractory multiple myeloma.

Beth Faiman, PhD, MSN, APRN-BC, AOCN, discusses the growing need for advanced practitioner provider education and her role with the NP/PA center of excellence.

Polatuzumab vedotin has been approved in combination with rituximab, cyclophosphamide, doxorubicin, and prednisone for previously untreated diffuse large B-cell lymphoma.

Omidubicel has been approved to quicken the recovery of neutrophils and reduce the risk of infection following stem cell transplant.

AbbVie has withdrawn the indications for previously pretreated patients with mantle cell lymphoma and marginal zone lymphoma.

To evaluate the prevalence of financial toxicity and observe the effect of Coverage and Cost-of-Care Links, a program providing financial navigation, investigators initiated a nonrandomized study.

Hematologists have developed a framework of the core symptoms caregivers should look out for when caring for a patient who has just received CAR T-cell therapy.

The primary overall survival analysis of the phase 3 ZUMA-7 trial favors axicabtagene ciloleucel over standard of care therapy.

Inpatient infusion was linked with greater comorbidity burden and increased likelihood of adverse effects in patients with follicular lymphoma who received CAR T-cell therapy, but not in those with mantle cell lymphoma.

Patients with multiple myeloma who received subcutaneous daratumumab experienced reduced clinic times compared with those who received the agent intravenously.

Siltuximab led to the complete resolution of cytokine release syndrome in 5 out of 6 patients, with a median time to complete response within 1 hour.

Linh Nguyen BSN, RN, OCN, BMTCN, highlights the benefits of prospective toxicity data collection for patients undergoing bone marrow transplantation.

Nurse researchers sought to improve the communication between the hematopoietic stem cell transplantation care team and pediatric patient caregivers.

During the 2023 Tandem Meeting, Trista Carelock RN, BSN, ONC, BMT-CN, highlighted how her institution leveraged remote patient monitoring to offer outpatient CAR T-cell therapy to patients.